116570 DTPA 0.3 (Boostrix)-012 EXT: 001: An open, phase III, non-randomized, multi-center study to assess the immunogenicity and safety of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced antigen content di

Project: Research project

Project Details

StatusFinished
Effective start/end date6/1/135/31/14

Funding

  • GlaxoSmithKline LLC
  • GlaxoSmithKline LLC